Agios Pharmaceuticals Insider Sells Shares Under Trading Plan
1 report, 1 independent
Updated Oct 23
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Sarah Gheuens sold 1,489 shares of Agios Pharmaceuticals stock on October 21, 2026, for a total transaction value of $55,882.17 at an average price of $37.53. This transaction, which was executed under a pre-arranged Rule 10b5-1 trading plan, was disclosed to the Securities & Exchange Commission. She also sold 500 shares of the company's stock on October 22, 2026.
From tickerreport.com
Why it matters
The transactions were filed with the Securities & Exchange Commission. Insider stock sales, even those executed under a pre-arranged trading plan, are disclosed and can reflect internal views on the company's valuation.
From tickerreport.com
Who's involved
- Agios PharmaceuticalsPublic American pharmaceutical company subject to regulatory oversight
- Sarah GheuensResearcher who serves as CMO and Head of R&D at Agios Pharmaceuticals
Keep exploring
The entities involved
-
Agios Pharmaceuticals
a public American pharmaceutical company
-
Sarah Gheuens
researcher
Nothing else this week.